Active Ingredient(s):Ibritumomab Tiuxetan FDA Approved: * February 19, 2002 Pharm Company: *IDEC PHARMACEUTICALS CORP Category:Cancer
Ibritumomab tiuxetan (pronounced /brtumomæb takstæn/), sold under the trade name Zevalin, is a monoclonal antibody radioimmunotherapy treatment for non-Hodgkin's lymphoma. The drug uses the monoclonal mouse IgG1 antibody ibritumomab in conjunction with the chelator tiuxetan, to which a radioactive isotope (either yttrium-90 or indium-111) is added. Tiuxetan is a modified version of DTPA whose carbon backbone contains an isothiocyanatobenzyl and a methyl group.&...
* May have multiple approval dates, manufacturers, or labelers. 1 Discussion